French allergy firm Stallergenes Greer is finally back on track with production at its facilities in Southern Paris, it reports in a press release.
Back in 2015, Stallergenes was ordered to stop all production and distribution based at its factory in Antony by the French National Agency for the Safety of Medicines and Health Products (ANSM). Some products were recalled in France.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.